Scientific considerations for pharmacoenhancers in antiretroviral therapy

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1128-1133

  Arya, Vikram ^a   Robertson, Sarah M ^a   Struble, Kimberly A ^a   Murray, Jeffrey S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

drug drug interactions; metabolism; pharmacoenhancer; pharmacokinetics; protease inhibitor; Ritonavir

Indexed keywords

COBICISTAT; DARUNAVIR; FOSAMPRENAVIR; INDINAVIR; MIDAZOLAM; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; NEPHROLITHIASIS; NONHUMAN; NOTE; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 84864404342     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011410569     Document Type: Note

References (20)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; January102011; 1-174. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed January 25, 2011.
2. Van Heeswijk RP, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1 infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther. 2001 ; 6: 201-229 (Pubitemid 34174760)
3. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003 ; 36: 1585-1592 (Pubitemid 36783344)
4. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2001 ; 2: 105-113 (Pubitemid 33114749)
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997 ; 337: 725-733 (Pubitemid 27417971)
6. Plosker GL, Scott LJ. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs. 2003 ; 63: 1299-1324 (Pubitemid 36750953)
7. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 ; 87: 322-329
8. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009 ; 85: 64-70
9. Durant J, Clevenbergh P, Garraffo RP, et al. Importance of protease inhibitors plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS. 2000 ; 14: 1333-1339 (Pubitemid 30459505)
10. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates of OATP1A2, OATP1B1, and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010 ; 20: 112-120
11. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with p-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol Pharm. 2004 ; 1: 49-56
12. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact. 2004 ; 150: 179-187 (Pubitemid 39463281)
13. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. Atazanavir: effects of P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 ; 33: 764-770 (Pubitemid 40686629)
14. Orman JS, Perry CM. Tipranavir: a review of its use in the management of HIV infection. Drugs. 2008 ; 68: 1435-1463 (Pubitemid 351916634)
15. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008 ; 42: 1048-1059
16. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol. 2002 ; 42: 1269-1274 (Pubitemid 35205064)
17. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004 ; 76: 73-84 (Pubitemid 38844736)
18. Penzak SR, Shen JM, Alfaro RM, et al. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit. 2004 ; 26: 322-330 (Pubitemid 38703022)
19. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 ; 311: 139-146 (Pubitemid 39287793)
20. Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother. 2005 ; 49: 4903-4910 (Pubitemid 41778900)